Tipsheet
What matters at India’s listed companies
Earnings · Pharmaceuticals · Micro cap

Ambalal Sarabhai confirms already-disclosed FY26 results

The board formally approved financial statements and routine administrative items in a session that adds nothing to prior disclosures.

1 earlier story on Ambalal Sarabhai Enterprises Ltd.
Mkt cap₹245 cr
P/E13.76×
ROE3.52%
Debt / eq.0.35
N/A No new financial data provided in this filing.

What's new

  • Ambalal Sarabhai formally adopted its audited FY26 financial results.
  • The board approved routine administrative agenda items including director reappointments.
  • The filing repeats financial details already released to the market.

Why this matters

This filing is purely procedural. The company has essentially rubber-stamped figures the market already has in its possession. There is no news here for investors to act on.

What we're watching

  • Any material updates to the business outlook beyond routine filings.
  • Future board meeting outcomes that deviate from standard administration.

The full read

Ambalal Sarabhai has provided a formal update following its latest board meeting, but it contains no fresh information. The audited standalone and consolidated financial results for the year ended March 31, 2026, were already released to the public in a prior filing. The board also cleared routine matters including director reappointments and standard inter-corporate loan approvals. Investors should treat this as a procedural housekeeping update. It provides no new insight into the company's performance or strategy.

Questions answered

Did Ambalal Sarabhai release new financial figures?
No. The results were previously disclosed, and this filing serves only as a formal board confirmation.
Mentioned: Ambalal Sarabhai Enterprises Ltd.
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Ambalal Sarabhai Enterprises Ltd.

Pharmaceuticals
₹253 cr
P/E 14.23×

Latest quarter · Mar 2026

Sales₹65 cr
Net profit₹6 cr
Op. margin+8.7%
EPS₹0.85

Strength & growth

Debt / equity0.35×
Current ratio0.98×
Sales CAGR+40.0%
EPS CAGR−12.9%
  1. 21 May 2026 · 7:52 PM IST Ambalal Sarabhai confirms already-disclosed FY26 results
  2. 61d ago Ambalal Sarabhai net profit jumps to ₹17.80 cr on tax write-backs